Cost-effectiveness in Moderate HTN Population - Brent Egan, MD

↳ This is a section part of Moment: CRT 2016 Technology & Innovation - Renal Denervation: New Data and Clinical Trial Design Update

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$29.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Cost-effectiveness in Moderate HTN Population presented by Brent Egan, MD at CRT 2016

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$29.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

Interventional Cardiologists
Interventional Fellows
Physicians with an interest in Resistant Hypertension

Session Name: Renal Denervation: New Data and Clincal Trial Design Update

Track: Technology & Innovation

Learning Objectives

Updates in Renal Denervation and Hypertension Therapies

Other Components in this Moment

Long-term Outcome of OUS Renal Denervation Trials - Felix Mahfoud, MD

SYMPLICITY 3 Longterm Outcome and Lessons Learned - Ajay Kirtane, MD, SM

Status of Renal Denervation Studies for Indications Beyond Hypertension, CHF, CKD, Sleep Apnea - Justin Davies, BSc, MBBS, PhD

Update on SPYRAL HTN Global Studies and Rationale for New Study Design - Felix Mahfoud, MD

Update on REINFORCE Study Rationale for Study Design - Michael Weber, MD

ReCor’s Trial Program - Ajay Kirtane, MD, SM

Long-term Outcome and Update on the ENLIGHTEN Study - Vasilios Papademetriou, MD, Dsc

Is There an Unmet Need for Device Treatment for Moderate Hypertension? - Brent Egan, MD

What is the Optimal Device Trial Design for Hypertension Therapy? - Michael Weber, MD

US Preventive Services Task Force Recommendation on ABPM Rationale/ Potential Implications - Michael Weber, MD

How Do I Treat Today’s Patients with Resistant Hypertension in My Practice? - Horst Sievert, MD, FSCAI

What Are the Primary Endpoints for Controlling Hypertension? Office vs. Ambulatory BP - Felix Mahfoud, MD

Why is There US Apathy Towards ABPM: Low Reimbursement or Cognitive Dissonance? - Krishna Rocha-Singh, MD, FSCAI

Cost-effectiveness in Moderate HTN Population - Brent Egan, MD

Loading Simple Education